AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows
GlobeAlert Desk · curated from South China Morning Post · East Asia
Shares of Akeso surged after British drug maker AstraZeneca moved to advance the Chinese biotech firm’s flagship cancer drug, while a new deal from US giant Merck further underscored the sector’s global momentum amid easing fears of US curbs. AstraZeneca on Tuesday announced a US$2 billion equity investment in Florida-headquartered Summit Therapeutics, which holds the exclusive rights to develop and commercialise Akeso’s immunotherapy drug ivonescimab outside China. Summit and AstraZeneca would...
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
What the desk knows about this story
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Single-source so far. Treat details as unconfirmed until more publishers report.
Not flagged as developing.
- Second jury cant agree on underworld murder chargeAttacks & Assaults · Japan · 4h ago
- Black clover season 2 episode 7 recap ending explained who killed megicula and what happened to gajaAttacks & Assaults · Japan · 9h ago
- Mother of japanese abducted by n. korea urges resolution 49 years onKidnappings · North Korea · 20h ago